Uncategorized

Is there Inherent Value in Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), DS Smith Plc (LSE:SMDS)?

Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) boasts a Price to Book ratio of 4.629647. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -9.302383, and a current Price to Earnings ratio of -8.244984. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.

As the next round of earnings reports come into the spotlight next quarter, investors may be deciding how to get into the best position to make the most profitable trades. Earnings reports have the ability to influence stock prices dramatically. Sometimes it can be hard to figure out which way the price will go even if the reported numbers are up to snuff. Some investors enjoy the frantic trading opportunities around earnings reports, and others will stay as far away as possible. Even if the investor isn’t planning on making any moves during earnings season, it may be wise to follow what companies are reporting. If the numbers from a certain holding come in way out of whack, it may be necessary to do some in-depth research to try and find out the reason. Investors that make sure that all the bases are covered will typically find it easier to make sense out of certain anomalies that pop up in the markets from time to time. Putting in the extra time and effort to understand the ins and outs of a particular stock may help boost the novice investor up to the next level. Every investor wants their trades to be profitable, and doing that little extra piece of homework could be just what the finance doctor ordered for staying on top of the stock market.    

There are many different tools to determine whether a company is profitable or not.  One of the most popular ratios is the “Return on Assets” (aka ROA).  This score indicates how profitable a company is relative to its total assets.  The Return on Assets for Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is -0.334845.  This number is calculated by dividing net income after tax by the company’s total assets.  A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength.  The score helps determine if a company’s stock is valuable or not.  The Piotroski F-Score of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 4.  A score of nine indicates a high value stock, while a score of one indicates a low value stock.  The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings.  It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue.  The score is also determined by change in gross margin and change in asset turnover.

Investors may be interested in viewing the Gross Margin score on shares of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO). The name currently has a score of 5.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) has a current MF Rank of 16253. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

Further, we can see that Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) has a Shareholder Yield of -0.018630 and a Shareholder Yield (Mebane Faber) of -0.04536. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

Checking in on some valuation rankings, Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) has a Value Composite score of 92. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 91.

Volatility/PI
Stock volatility is a percentage that indicates whether a stock is a desirable purchase.  Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year.  The Volatility 12m of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 53.959200.  This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized.  The lower the number, a company is thought to have low volatility.  The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months.  The Volatility 3m of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 47.029400.  The Volatility 6m is the same, except measured over the course of six months.  The Volatility 6m is 49.445400.

The Price Index is a ratio that indicates the return of a share price over a past period. The price index of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for last month was 1.04755. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 0.52591.

One way to completely avoid market mistakes is to not invest at all. Of course, that could end up to be the greatest mistake of all. Investors will occasionally make some mistakes, as that comes with the territory. The key as with most things in life is to figure out how to learn from past mistakes and use that knowledge to make better decisions going forward. Pinpointing exactly what went wrong may help shed some light on what needs improvement. Sometimes, investors will suffer losses and become discouraged right out of the gate. The tendency is to then try to recoup losses by taking even bigger risks which can lead to complete disaster. One of the biggest differences between successful investors and failed investors is the willingness and ability to learn from past personal mistakes.

DS Smith Plc (LSE:SMDS) has a Price to Book ratio of 1.459609. This ratio has been calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of 9.543600, and a current Price to Earnings ratio of 16.718221. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.

New investors may be trying to figure out the best way to build a solid foundation with which to make future investing decisions. There are many different paths that an investor can take once they become familiar with the territory. Some investors will choose to study professional analyst research and recommendations. This can be very useful, but many investors may feel more comfortable doing their own research. Conducting stock research may involve looking at the fundamentals of a certain company. Understanding what kind of competitive advantage a company might have compared to others in their industry may help weed out some of the more undesirable stocks. Because there is no one way to properly conduct stock research, investors may need to try a few different methods in order to determine the best individual course of action.

DS Smith Plc (LSE:SMDS) has a current MF Rank of 4713. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

There are many different tools to determine whether a company is profitable or not.  One of the most popular ratios is the “Return on Assets” (aka ROA).  This score indicates how profitable a company is relative to its total assets.  The Return on Assets for DS Smith Plc (LSE:SMDS) is 0.044312.  This number is calculated by dividing net income after tax by the company’s total assets.  A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength.  The score helps determine if a company’s stock is valuable or not.  The Piotroski F-Score of DS Smith Plc (LSE:SMDS) is 7.  A score of nine indicates a high value stock, while a score of one indicates a low value stock.  The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings.  It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue.  The score is also determined by change in gross margin and change in asset turnover.

Further, we can see that DS Smith Plc (LSE:SMDS) has a Shareholder Yield of -0.240792 and a Shareholder Yield (Mebane Faber) of -0.26407. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

Volatility/PI
Stock volatility is a percentage that indicates whether a stock is a desirable purchase.  Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year.  The Volatility 12m of DS Smith Plc (LSE:SMDS) is 29.557600.  This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized.  The lower the number, a company is thought to have low volatility.  The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months.  The Volatility 3m of DS Smith Plc (LSE:SMDS) is 30.101700.  The Volatility 6m is the same, except measured over the course of six months.  The Volatility 6m is 34.193700.

The Price Index is a ratio that indicates the return of a share price over a past period. The price index of DS Smith Plc (LSE:SMDS) for last month was 1.03335. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for DS Smith Plc (LSE:SMDS) is 0.63500.

Checking in on some valuation rankings, DS Smith Plc (LSE:SMDS) has a Value Composite score of 24. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 39.

Investors may be interested in viewing the Gross Margin score on shares of DS Smith Plc (LSE:SMDS). The name currently has a score of 59.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

Investors might be trying to figure out the best way to approach the stock market. After creating a plan that includes a list of stocks to purchase, investors may be looking to gauge the best time to enter the trade. With markets still cruising along at high altitudes, investors may be worried about buying at the top. Most individuals would probably agree that getting out before the market drops would be the best play. Obviously this is much easier said than done. If the warning signs were blatant, everyone would know exactly when to sell and when to re-buy. When the stock market has a big decline, the natural instinct is generally to sell in order to protect gains or eliminate further losses. Trying to time the market can have negative implications for investors who are not prepared to handle extremely volatile market conditions. Being prepared for any sudden change in the overall economy or stock market conditions may help the investor stay afloat for the long haul.

Leave a Reply

Your email address will not be published. Required fields are marked *

*